Gene Therapy Deals Are Up 1700% in 2026 — Here's the Data

Thirty-six gene therapy deals closed between March and September 2026 — a +1700% increase over the prior six-month window (September 2025 to March 2026), which produced exactly two. This is not a gradual warming; it is a phase transition driven by large pharma companies concluding, almost simultaneously, that in vivo gene therapy has crossed a clinical and manufacturing inflection point that justifies billion-dollar bets.

The Data — Gene Therapy Deal Activity, Period over Period

A base of 2 makes the percentage look dramatic, and it is — but 36 transactions in six months is an absolute number that matters on its own. For context, Deal Benchmarks data across all modalities shows that gene therapy accounted for roughly 3% of biopharma licensing volume in late 2025. By mid-2026, that share has jumped to an estimated 11–13%, depending on how you classify gene-editing hybrids. The modality is no longer niche.

What's Driving the Trend

Manufacturing cost curves finally bent. AAV vector manufacturing costs dropped roughly 40–50% between 2023 and early 2026, driven by suspension-culture scale-up, improved upstream titers, and the emergence of contract capacity from players like Catalent (now part of Novo Holdings) and Forge Biologics. When cost-of-goods drops below $150K per dose for many indications, the commercial math changes fundamentally — gene therapies move from ultra-rare-only propositions to viable candidates in larger patient populations like heart disease and metabolic disorders. That is exactly the bet Eli Lilly placed with its $2.3B Verve Therapeutics deal.

Regulatory signals cleared the fog. The FDA's 2025 draft guidance on in vivo gene therapy durability endpoints gave sponsors a clearer path to accelerated and even standard approvals without decade-long follow-up. Two gene therapy approvals in Q1 2026 — including one for a non-rare indication — served as proof points that the agency is not going to gate-keep this modality to death. That regulatory de-risking unlocked BD budgets that had been frozen since the Bluebird Bio commercial struggles of 2023–2024.

Big Pharma pipeline gaps are acute. AbbVie's immunology franchise faces biosimilar erosion post-Humira, and its ophthalmology ambitions need next-generation assets — hence the REGENXBIO deal. Lilly, flush with GLP-1 revenue, is deploying capital into cardiovascular and genetic medicine at a pace we haven't seen since Pfizer's post-Lipitor diversification era. These are not exploratory option deals; they are strategic pipeline fills with real upfront capital.

Notable Deals

The Verve–Lilly transaction is the marquee deal and arguably the most important gene therapy licensing event of the decade. A $1B upfront for a cardiovascular gene-editing program signals that Lilly views PCSK9-targeted gene therapy not as a science experiment but as a franchise play. The $2.3B total deal value puts it in the top 5% of all biopharma licensing transactions by TDV in 2026, per Deal Benchmarks. This is a conviction bet, not an option.

Lilly's double-tap on Engage Bio — two deals in consecutive days totaling ~$402M — is equally telling. It suggests Lilly is locking up delivery technology (likely next-gen capsid or LNP-based platforms) alongside therapeutic programs. Platform deals in gene therapy are accelerating because every pharma company that wants to play in this space realizes that vector/delivery IP is the bottleneck, not target biology.

The MeiraGTx–Oberland Capital deal is structurally different: a $400M royalty financing arrangement, not a traditional license. This reflects a growing trend where gene therapy companies monetize future royalty streams from approved or late-stage products to fund pipeline expansion without dilution. Expect more of these structures as gene therapy revenues begin to materialize at scale.

The REGENXBIO–AbbVie deal, while undisclosed in financial terms, is strategically significant. REGENXBIO's NAV vector platform has been the subject of licensing disputes and competitive positioning for years. AbbVie's entry likely secures exclusive or co-exclusive rights for specific indications — probably ophthalmology — and removes a key platform from the open market.

What This Means for BD Teams Right Now

If you're selling gene therapy assets, this is a seller's market — but the window has a ceiling. The surge from 2 to 36 deals means buyer appetite is intense, but it also means the best assets are being snapped up quickly. Verve's $1B upfront sets an anchor that will pull comparable programs' valuations higher. If you have clinical-stage gene therapy data, you should be running a competitive process now, not in Q4. The Lilly and AbbVie moves will pressure other large pharma players (Roche, Novartis, Pfizer) to respond, and that competitive dynamic favors licensors for the next 6–12 months.

Upfront-heavy structures are back. The Verve deal's 43% upfront-to-TDV ratio ($1B / $2.3B) is well above the biopharma median of ~20–25% for Phase 2 assets. This reflects both Lilly's urgency and Verve's leverage. BD teams should benchmark their term sheets against this ratio using Solidus to ensure they're not leaving value on the table.

Platform deals are commanding premiums. The Engage Bio and REGENXBIO transactions confirm that delivery technology — capsids, tissue-tropic vectors, non-viral systems — is being valued independently of any single therapeutic program. If your company has differentiated delivery IP, consider structuring a platform license separately from program-specific deals. The combined value will almost certainly exceed a single bundled transaction.

If you're buying, move now but structure for risk. The 1700% surge will attract attention from every BD team at JP Morgan 2027. Deals done in Q3–Q4 2026 will look cheaper than deals done in Q1 2027 once the herd arrives. That said, gene therapy still carries manufacturing and durability risk. Use milestone-heavy structures with clinical and commercial triggers, and negotiate robust CMC audit rights. The Oberland-style royalty financing model also offers buyers an alternative: fund a gene therapy company's development in exchange for economics, rather than licensing IP outright.

Benchmark your deal against current market rates — use the Ambrosia calculator to see where your term sheet falls relative to the 36 gene therapy transactions closed this period. Knowing whether your upfront, milestones, and royalty rates are at, above, or below market is no longer optional when deal velocity is this high.